Table 2.
Change in retinal layer thickness during follow‐up for symptomatic patients and controls.
|
Baseline (P = 20, C = 29) |
Year 1 (P = 20, C = 22) |
Year 2 (P = 17, C = 26) |
Change (95% CI) | p‐value | ||
|---|---|---|---|---|---|---|
| pRNFL (total) a , µm | patient | 86.83 (2.55) | 85.17 (2.55) | 85.01 (2.56) | −1.82 (−2.68 to −0.97) | <0.001 |
| control | 92.19 (2.07) | 92.63 (2.07) | 92.32 (2.07) | 0.13 (−0.98 to 1.25) | ||
| Superior | patient | 103.88 (3.48) | 104.13 (3.48) | 104.19 (3.49) | 0.32 (−0.86 to 1.50) | 0.874 |
| control | 116.52 (2.88) | 117.13 (2.89) | 117.00 (2.88) | 0.48 (−1.36 to 1.80) | ||
| Nasal | patient | 70.80 (2.93) | 66.63 (2.93) | 65.63 (2.97) | −5.17 (−7.27 to −3.06) | <0.001 |
| control | 66.26 (2.34) | 67.25 (2.37) | 65.80 (2.35) | −0.46 (−2.80 to 1.86) | ||
| Inferior | patient | 112.83 (3.35) | 110.93 (1.04) | 110.82 (4.05) | −2.00 (−3.07 to −0.94) | 0.002 |
| control | 115.14 (3.18) | 115.45 (3.19) | 114.95 (3.19) | −0.19 (−1.69 to 1.31) | ||
| Temporal | patient | 59.83 (2.69) | 59.00 (2.69) | 59.32 (2.70) | −0.51 (−1.67 to −0.66) | 0.254 |
| control | 70.85 (2.43) | 70.66 (2.44) | 71.56 (2.44) | 0.72 (−0.52 to 2.08) | ||
| RNFL, µm | patient | 30.71 (0.79) | 31.43 (0.79) | 30.91 (0.79) | 0.19 (−0.31 to 0.70) | 0.140 |
| control | 34.21 (0.68) | 33.97 (0.68) | 34.09 (0.68) | −0.12 (−0.70 to 0.45) | ||
| GCL, µm | patient | 36.54 (0.85) | 36.38 (0.85) | 35.99 (0.85) | −0.55 (−0.81 to −0.29) | 0.014 |
| control | 37.81 (0.68) | 37.61 (0.69) | 37.69 (0.68) | −0.11 (−0.45 to 0.22) | ||
| EDSS | 4.0 (0‐7.0) | 5.0 (1.5‐7.5) | 6.0 (2.0‐7.5) | 0.47 (0.01 to 0.93) | 0.045 | |
| SSPROM | 80.25 ± 9.94 | 79.65 ± 9.11 | 75.27 ± 11.78 | −3.71 (−6.76 to −0.65) | 0.021 | |
| Timed up‐and‐go, s | 8.45 ± 2.84 | 8.68 ± 2.98 | 9.45 ± 2.99 | 0.96 (−0.04 to 1.95) | 0.058 |
Retinal layer thickness and changes during follow‐up are the estimated values from the linear mixed‐effects models and summarized as means (standard errors). pRNFL (total) and GCL thickness are also presented in Figure 3 (red lines for symptomatic patients, blue lines for controls). P‐values represent the significance level of the interaction term “group * time” and signify whether change in retinal layer thickness over time of patients differs from controls. For patients, change on clinical parameters is also reported. Values are summarized as mean ± SD or median (range) depending on the distribution of the data; change is reported as mean paired change between baseline and year 2 with corresponding p‐value (paired t‐test/Wilcoxon signed rank test).
EDSS, Expanded Disability Status Scale; GCL, ganglion cell layer; pRNFL, peripapillary retinal nerve fiber layer; RNFL, retinal nerve fiber layer; SSPROM, Severity Scoring system for Progressive Myelopathy.
Mean thickness of the total peripapillary ring followed by each of the four quadrants.